Proteogenomics: A Novel Method To Study Biologic Factors of Ovarian Cancer

Proteogenomics: A Novel Method To Study Biologic Factors of Ovarian Cancer
A recent study led by researchers at the Pacific Northwest National Laboratory (PNNL) and Johns Hopkins Medical Institutions (JHMI) demonstrated the usefulness of combining genomic and proteomic data known as proteogenomics to gain new insights about biological factors responsible for ovarian cancer. Results from the study, “Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer,” were published in Cell. Though some progress has been made in the fight against ovarian cancer, the underlying mechanisms are still not fully understood. This is particularly related to the lack of suitably advanced analysis methods capable of providing a full view of the disease governing mechanisms. Researchers developed a promising novel method based on the combination of genomics and proteomics: proteogenomics, a powerful method to gain insights into the development and progress of the most malignant forms of ovarian cancer. "Historically, cancer's been looked at as a disease of the genome," Karin Rodland, a senior author of the study and chief scientist for biomedical research at PNNL, said in a press release. "But that genome has to express itself in functional outcomes, and that's what the proteomic data adds, because proteins do the actual work of the genome." Daniel W. Chan, the study's other senior author, who led the team at Johns Hopkins  said
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *